Pfizer Inc. (NYSE:PFE) Given Average Recommendation of “Hold” by Analysts

Shares of Pfizer Inc. (NYSE:PFE) have received an average recommendation of “Hold” from the twenty-three research firms that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $28.0476.

Several research analysts recently commented on PFE shares. HSBC reiterated a “buy” rating and issued a $29.00 target price on shares of Pfizer in a report on Wednesday, December 10th. Citigroup began coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price on the stock. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research note on Thursday, February 12th. Royal Bank Of Canada assumed coverage on Pfizer in a research report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective for the company. Finally, Bank of America lowered their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th.

Pfizer Stock Performance

Shares of PFE opened at $26.60 on Wednesday. The business’s 50 day moving average is $26.20 and its two-hundred day moving average is $25.44. The firm has a market cap of $151.25 billion, a price-to-earnings ratio of 19.56 and a beta of 0.47. Pfizer has a 52-week low of $20.92 and a 52-week high of $27.94. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period last year, the company earned $0.63 earnings per share. Analysts forecast that Pfizer will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is currently 126.47%.

Hedge Funds Weigh In On Pfizer

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares during the last quarter. State Street Corp grew its stake in Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock valued at $7,481,085,000 after acquiring an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after buying an additional 1,184,728 shares in the last quarter. Norges Bank bought a new position in shares of Pfizer in the second quarter worth approximately $2,270,157,000. Finally, Morgan Stanley raised its position in shares of Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after buying an additional 14,342,946 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: PF-07328948 kidney-function Phase 1 progress — Pfizer updated an ongoing study that management says supports long‑term pipeline value, reinforcing future R&D upside. Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value
• Positive Sentiment: Oncology milestones broaden non‑COVID revenue path — Phase 3 PADCEV + Keytruda data and a full FDA approval for a BRAFTOVI regimen are material near‑term clinical wins that boost recurring oncology revenue prospects. Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues
• Positive Sentiment: Dividend/defensive narrative supports demand — MarketBeat highlights Pfizer’s 6%+ yield and defensive appeal amid volatility, which can attract income‑seeking flows into PFE. The Dividend Safe Harbor: 2 Stocks to Watch
• Positive Sentiment: Analyst upgrade — Argus raised Pfizer to Buy with a $35 target, signaling upside from current levels and likely supporting positioning by discretionary investors. Benzinga coverage of Argus upgrade
• Neutral Sentiment: AI adoption in manufacturing — A market report cites Pfizer among majors integrating AI (predictive maintenance, quality control). It’s a positive long‑term efficiency story but not an immediate revenue catalyst. AI in Pharma Manufacturing Market Research 2026-2040
• Neutral Sentiment: “Quiet cash comeback” narrative — Commentary on improving cash generation supports the valuation case, but it’s an incremental theme rather than a single price mover. Pfizer’s Quiet Cash Comeback
• Negative Sentiment: Zumrad EMA filing withdrawn — Pfizer pulled its Zumrad application in Europe, a clear regulatory setback that removes a near‑term approval pathway and can pressure sentiment. Pfizer withdraws Zumrad EMA filing
• Negative Sentiment: CEO flags issues with FDA vaccine leadership — Public criticism of the FDA’s vaccine leadership introduces regulatory uncertainty and could complicate future review processes or timelines. Pfizer CEO flags issues with FDA’s vaccine leadership

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.